Patient-Centric Rare Diseases Care: From Rhetoric to Commitment

Every February, around Rare Disease Day, a familiar phrase dominates conferences, institutional statements, policy forums, and corporate communications: “The patient is at the center.” Public buildings are illuminated, symbolic gestures multiply, and all stakeholders — governments, healthcare professionals, industry, and patient organizations — appear aligned around the same message.

Yet, this moment of collective visibility invites a necessary and uncomfortable question: Is the patient truly at the center of the rare disease ecosystem, or has the phrase become an overused slogan disconnected from daily practice?

Rare diseases are not abstract conditions. They are often progressive, multisystemic, and life-altering. Delays in diagnosis, access, or coordinated care have measurable consequences for survival, functionality, and quality of life. Therefore, placing the patient at the center cannot remain a rhetorical commitment. It must translate into concrete, sustained, and measurable actions.

This article examines what patient-centeredness should genuinely mean in rare diseases, stakeholder by stakeholder, and what each actor must do — beyond symbolic gestures — to make the concept real.

Rare Diseases: A Shared Social Challenge

Rare diseases are defined differently across regions, but globally they affect a significant population. The World Health Organization and Orphanet estimate that there are over 7,000 rare diseases, affecting 6–8% of the global population — approximately 300 million people worldwide (1,2). In Mexico alone, estimates suggest 7–8 million people live with a rare disease, directly impacting millions of families and caregivers (3).

Despite this scale, rare diseases remain largely invisible in public discourse, health system planning, and medical education. This invisibility is one of the central reasons why delays in diagnosis and care continue to occur.

Society: Awareness as the First Diagnostic Tool

The patient’s journey does not begin in a hospital, it begins in society. Families, schools, workplaces, and communities are often the first to notice that something is “not quite right:” persistent fatigue, delayed motor development, recurrent infections, unexplained pain, or sensory impairment.

Population-level awareness plays a critical role in early detection. Studies consistently show that lack of public understanding of rare diseases contributes to delayed medical consultation and normalization of symptoms (4). When families are unaware that rare diseases exist, they may accept progressive deterioration as inevitable or unrelated events.

Putting the patient at the center at the societal level means:

• Normalizing conversations about rare diseases.

• Encouraging families to seek medical evaluation early.

• Reducing stigma and isolation.

• Supporting second opinions and specialist referrals.

Awareness does not diagnose disease—but it saves time, and in rare diseases, time is a decisive variable.

Public Officials: From Symbolic Recognition to Structural Action

Public officials often play a visible role during Rare Disease Day: official messages, public events, symbolic lighting, and commemorations. While visibility matters, patient-centered care cannot be built on symbolism alone.

Health system performance indicators show that delays in regulatory decisions, fragmented financing, and administrative bottlenecks significantly affect rare disease outcomes (5). In Mexico, for example, while COFEPRIS has issued over 100 orphan drug recognitions since the late 2000s, only a fraction of these therapies are consistently available across public institutions such as IMSS or ISSSTE (6).

Placing the patient at the center requires public officials to:

• Accelerate regulatory and reimbursement processes.

• Ensure continuity of funding for diagnosis and treatment.

• Align federal and institutional policies.

• Reduce bureaucratic barriers that disproportionately affect rare disease patients.

Patients do not experience health policy as frameworks, they experience it as waiting lists, denials, and delays.

Legislators: Building the Legal Infrastructure of Access

Legislative action defines whether patient-centered care is sustainable or dependent on discretionary decisions. Countries with comprehensive rare disease strategies show better outcomes in diagnosis, registries, and access (7).

In Mexico, the General Health Law recognizes rare diseases, but lacks a fully operational national rare disease framework, including:

• A mandatory national rare disease registry.

• Specific access pathways.

• Defined timelines for diagnosis and treatment.

• Legal protection for families and caregivers.

True patient-centeredness demands that legislators move beyond declarations and build enforceable rights, including early diagnosis, access to specialized care, and financial protection (8).

Without legislation, patient care depends on goodwill rather than guarantees.

Physicians: Suspicion, Referral, and Humility

Physicians are often the first medical contact; yet, rare diseases are underrepresented in undergraduate and postgraduate training worldwide (9). This is not a personal failure, it is a structural one.

However, early suspicion and timely referral remain among the most powerful tools to reduce diagnostic delay. Studies show that patients with rare diseases may consult six to eight specialists over five to eight years before receiving a diagnosis (10).

Placing the patient at the center means that physicians:

• Recognize when symptoms do not fit common patterns.

• Refer early to genetics or specialized centers.

• Avoid prolonged follow-ups without diagnostic clarity.

• Listen carefully to patient and caregiver narratives.

Clinical humility — acknowledging uncertainty — can save years of irreversible damage.

5. Healthcare Professionals: The Invisible Accelerators

Nurses, social workers, and allied health professionals are critical but often overlooked stakeholders. Evidence shows that care coordination and patient navigation significantly improve access and outcomes in rare diseases (11).

These professionals:

• Help families navigate complex systems.

• Reduce administrative burden.

• Facilitate continuity of care.

• Provide emotional and practical support.

A patient-centered ecosystem recognizes that care is not delivered by physicians alone.

Pharmaceutical Industry: Aligning Purpose With Practice

The pharmaceutical industry frequently emphasizes patient centricity, and in rare diseases, it has played an important role in:

However, true patient-centeredness requires alignment between discourse and decision-making. Studies on orphan drug markets show tension between financial sustainability and access, particularly in middle-income countries (12).

Industry commitment should be reflected in:

• Support for early diagnosis, even before treatment availability.

• Long-term educational investment.

• Transparent access strategies.

• Outcome-based value frameworks.

Patients cannot be a slogan, they must be a measurable outcome.

Patient Organizations: Visibility With Responsibility

Patient organizations are essential pillars of the rare disease ecosystem. Many provide daily, life-changing support. However, international literature also warns against visibility without impact (13).

Patient-centered advocacy means:

• Supporting real cases, not only events.

• Providing accurate, evidence-based information.

• Acting as effective bridges between stakeholders.

• Avoiding politicization that delays care.

Legitimacy is earned through sustained support, not public exposure alone.

Families and Caregivers: The Silent Backbone

Caregivers, predominantly women, carry the greatest invisible burden in rare diseases. Studies show that over 70% of primary caregivers are female, often leaving the workforce and experiencing financial and psychological stress (14).

Patient-centered care must include caregivers by:

• Recognizing unpaid care.

• Providing psychosocial support.

• Protecting economic stability.

• Offering education and empowerment.

A patient cannot be at the center if the caregiver collapses at the margins.

From Language to Accountability

Saying “the patient is at the center” is easy. Building systems that reflect it is not. Rare diseases expose the gaps between intention and execution, between celebration and accountability.

This February, beyond symbolic gestures, every stakeholder must ask: What am I doing — today, in practice — to place the patient truly at the center?

In rare diseases, time is not neutral. Every delay has a cost. Every decision matters.

Sources:

1. World Health Organization. Priority diseases and reasons for inclusion.

2. Orphanet. Rare disease epidemiology and classification.

3. Secretaría de Salud / COFEPRIS. Enfermedades raras en México.

4. EURORDIS. The Voice of Rare Disease Patients in Europe.

5. OECD. Health system performance and access to innovative medicines.

6. COFEPRIS. Orphan drug recognitions and regulatory framework.

7. European Commission. National plans and strategies for rare diseases.

8. Ley General de Salud (México).

9. Ferreira CR. The burden of rare diseases. Am J Med Genet.

10. Faye F et al. Time to diagnosis in rare diseases. Eur J Hum Genet.

11. Pelentsov LJ et al. Care coordination in rare diseases. Orphanet J Rare Dis.

12. IQVIA Institute. Global orphan drug trends.

13. Facey KM et al. Patient involvement in rare diseases. Health Policy.

14. Global Genes. Rare disease caregiving burden report.